Pharming Reports Positive Leniolisib Results in Phase II PID Trial
The 13-person study found reductions in spleen and lymph-node measures, while all 12 participants who completed it entered an extension.
Key takeaways
- Spleen volume fell by a mean 26.4% in 11 evaluable participants.
- All 12 participants who completed the study enrolled in a three-year extension.
Pharming reported positive topline results from a Phase II trial of leniolisib in 13 people with genetically identifiable primary immunodeficiencies and immune dysregulation. The company said spleen volume fell by a mean 26.4% among 11 evaluable participants.
Mean index lymph-node lesion size declined 33.7% among four evaluable participants. In seven people with impaired gas exchange at baseline, predicted lung diffusing capacity rose by a mean 8.0%; liver stiffness improved in two of three participants with elevated stiffness at baseline.
Pharming said the treatment was generally well tolerated, with no new safety signals. All 12 participants who completed the study enrolled in a three-year extension.
At the Oct. 13 close, Pharming shares traded at €0.845, down 3.43% from the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.
